Eurofins Scientific/€ERF
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Eurofins Scientific
Eurofins Scientific, with the ticker ERF, is a global bio-analytical testing providing services across several industries including pharmaceutical, food, environmental, and consumer products. Founded in 1987, the company specializes in delivering analytical testing and advisory services to ensure product safety and compliance with regulations. Eurofins operates through a decentralized network of laboratories, serving customers worldwide to enhance health and safety standards.
- Ticker
- €ERF
- Sector
- Health
- Primary listing
- PAR
- Employees
- 65,000
- Headquarters
- Luxembourg, Luxembourg
- Website
- www.eurofins.com
ERF Metrics
BasicAdvanced
€13B
29.50
€2.56
0.84
€0.72
0.95%
Price and volume
Market cap
€13B
Beta
0.84
52-week high
€76.84
52-week low
€56.52
Average daily volume
369K
Dividend rate
€0.72
Financial strength
Current ratio
1.132
Quick ratio
0.874
Long term debt to equity
0.795
Total debt to equity
0.961
Dividend payout ratio (TTM)
37.12%
Interest coverage (TTM)
6.16%
Profitability
EBITDA (TTM)
1,537.1
Gross margin (TTM)
23.13%
Net profit margin (TTM)
7.17%
Operating margin (TTM)
14.08%
Effective tax rate (TTM)
27.37%
Revenue per employee (TTM)
€110,000
Management effectiveness
Return on assets (TTM)
5.99%
Return on equity (TTM)
11.33%
Valuation
Price to earnings (TTM)
29.498
Price to revenue (TTM)
1.803
Price to book
3.63
Price to tangible book (TTM)
-7.47
Price to free cash flow (TTM)
19.56
Free cash flow yield (TTM)
5.11%
Free cash flow per share (TTM)
3.858
Dividend yield (TTM)
0.95%
Forward dividend yield
0.95%
Growth
Revenue change (TTM)
3.38%
Earnings per share change (TTM)
28.88%
3-year revenue growth (CAGR)
4.30%
10-year revenue growth (CAGR)
12.29%
3-year earnings per share growth (CAGR)
6.98%
10-year earnings per share growth (CAGR)
18.96%
3-year dividend per share growth (CAGR)
-10.37%
10-year dividend per share growth (CAGR)
17.38%
What the Analysts think about ERF
Analyst ratings (Buy, Hold, Sell) for Eurofins Scientific stock.
Analyst projections of the future price of Eurofins Scientific stock.
Bulls say / Bears say
Eurofins’ H1 results show improving earnings quality: EPS rose 29%, adjusted EBITDA rose 8%, and the adjusted EBITDA margin widened to 23.7% from 22.4%. Free cash flow before investment in owned sites increased 33%, while cash conversion improved to 47% from 36%. (MarketScreener)
The completed hub-and-spoke network and digitalisation programme could provide further operating leverage after the current investment phase. Eurofins is already close to its 24% 2027 EBITDA margin target and still expects cash conversion above 50% by 2027. (MarketScreener, Euronext)
The planned $400m purchase of Element’s North American Life Sciences Testing Services business would add more than $150m of 2026 revenue across 27 facilities. It strengthens Eurofins’ presence in underrepresented North American regions and gives the group scope to apply its existing laboratory network and scale. (Finanzwire)
H1 organic growth was only 2.7%, below Eurofins’ mid-single-digit 2026 target and 6.5% long-term objective. Biopharma remained soft, so meeting guidance requires a significant second-half acceleration that analysts view as uncertain. (MarketScreener, MarketScreener)
Clinical Diagnostics is facing a deliberate revenue drag as Eurofins rationalises loss-making contracts in Spain and Italy and exits its Netherlands business. Management expects better returns eventually, but the actions weaken near-term growth while other divisions are already soft. (Euronext)
Valuation could come under pressure if growth does not improve: Morgan Stanley cut Eurofins to underweight and lowered its target to €64.50 from €68.50. The bank said organic growth remains below peers and the medium-term target, and that a profit warning could not be ruled out. (MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 29 Sept 2026.
ERF Financial Performance
Revenues and expenses
ERF Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ERF
AllEURGBPUSD
Fund name | Fund size | €ERF weighting |
|---|---|---|
iShares EURO STOXX Mid€DJMC | €572M | 1.07% |
iShares EURO STOXX Mid Cap£DJMC | £491M | 1.07% |
iShares MSCI Europe Health Care Sector€ESIH | €863M | 0.54% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 0.54% |
iShares STOXX Europe Mid 200€EXSD | €610M | 0.53% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.